CTLA4 and pneumonitis: The odds ratio (OR) was 3.00 [95% CI (1.60, 5.64); p < 0.01], indicating a significantly higher incidence of any-grade pneumonitis in patients treated with CTLA-4 inhibitors compared to the control group (Figure 6).